Immunoglobulin plus firsekibart for Kawasaki disease
Treatments studied
Part of Blood & lymphatic, Heart & circulation, Skin clinical trials.
This trial tests adding a new drug, firsekibart, to standard immunoglobulin treatment for children with Kawasaki disease. The goal is to see if the combination is safe and works better than immunoglobulin alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child has been diagnosed with Kawasaki disease within the first 10 days of fever
- Your child has not yet received intravenous immunoglobulin therapy
- Your child is older than 28 days and younger than 18 years
- Your child does not have a known allergy to immunoglobulins, firsekibart, or similar components
- Your child is not currently on steroids or other immune-suppressing medications
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two treatments—anakinra and IVIG—for children with Kawasaki disease who still have fever after their first standard IVIG treatment. It aims to find which option works better and is safer for “IVIG non-responders” who may be at risk for heart complications.
This trial tests whether anakinra is at least as effective as standard treatment for children with Kawasaki disease. It aims to prevent heart complications caused by inflammation in the blood vessels.
This trial is testing a way to match children with Kawasaki disease to the best treatment. It looks at specific symptoms and fever duration to see if a child qualifies for the study, which may help doctors give the right treatment faster.
This trial tests whether a cholesterol-lowering medication called atorvastatin can help children whose hearts were damaged by Kawasaki disease (a serious childhood illness that inflames blood vessels). The study may help reduce long-term heart complications.
This study looks at children with Kawasaki disease, a condition that causes inflammation in blood vessels. The goal is to learn more about how it affects kids in Europe and North India.
This study tests the best dose of a blood thinner called rivaroxaban for children with a giant coronary artery aneurysm after Kawasaki disease. The goal is to prevent dangerous blood clots.
Hear when a new Kawasaki Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.